These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
569 related articles for article (PubMed ID: 26357964)
1. Macitentan inhibits the transforming growth factor-β profibrotic action, blocking the signaling mediated by the ETR/TβRI complex in systemic sclerosis dermal fibroblasts. Cipriani P; Di Benedetto P; Ruscitti P; Verzella D; Fischietti M; Zazzeroni F; Liakouli V; Carubbi F; Berardicurti O; Alesse E; Giacomelli R Arthritis Res Ther; 2015 Sep; 17(1):247. PubMed ID: 26357964 [TBL] [Abstract][Full Text] [Related]
2. Effects of macitentan and its active metabolite on cultured human systemic sclerosis and control skin fibroblasts. Cutolo M; Montagna P; Brizzolara R; Smith V; Alessandri E; Villaggio B; Sulli A; Tavilla PP; Pizzorni C; Soldano S J Rheumatol; 2015 Mar; 42(3):456-63. PubMed ID: 25593238 [TBL] [Abstract][Full Text] [Related]
3. The Endothelial-mesenchymal Transition in Systemic Sclerosis Is Induced by Endothelin-1 and Transforming Growth Factor-β and May Be Blocked by Macitentan, a Dual Endothelin-1 Receptor Antagonist. Cipriani P; Di Benedetto P; Ruscitti P; Capece D; Zazzeroni F; Liakouli V; Pantano I; Berardicurti O; Carubbi F; Pecetti G; Turricchia S; Alesse E; Iglarz M; Giacomelli R J Rheumatol; 2015 Oct; 42(10):1808-16. PubMed ID: 26276964 [TBL] [Abstract][Full Text] [Related]
4. Bosentan and macitentan prevent the endothelial-to-mesenchymal transition (EndoMT) in systemic sclerosis: in vitro study. Corallo C; Cutolo M; Kahaleh B; Pecetti G; Montella A; Chirico C; Soldano S; Nuti R; Giordano N Arthritis Res Ther; 2016 Oct; 18(1):228. PubMed ID: 27716320 [TBL] [Abstract][Full Text] [Related]
5. Dual Blockade of TGF-β Receptor and Endothelin Receptor Synergistically Inhibits Angiotensin II-Induced Myofibroblast Differentiation: Role of AT Duangrat R; Parichatikanond W; Mangmool S Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108136 [TBL] [Abstract][Full Text] [Related]
6. Disruption of transforming growth factor beta signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma. Ghosh AK; Bhattacharyya S; Lakos G; Chen SJ; Mori Y; Varga J Arthritis Rheum; 2004 Apr; 50(4):1305-18. PubMed ID: 15077315 [TBL] [Abstract][Full Text] [Related]
7. The nuclear receptor constitutive androstane receptor/NR1I3 enhances the profibrotic effects of transforming growth factor β and contributes to the development of experimental dermal fibrosis. Avouac J; Palumbo-Zerr K; Ruzehaji N; Tomcik M; Zerr P; Dees C; Distler A; Beyer C; Schneider H; Distler O; Schett G; Allanore Y; Distler JH Arthritis Rheumatol; 2014 Nov; 66(11):3140-50. PubMed ID: 25155144 [TBL] [Abstract][Full Text] [Related]
8. Intracellular TGF-beta receptor blockade abrogates Smad-dependent fibroblast activation in vitro and in vivo. Ishida W; Mori Y; Lakos G; Sun L; Shan F; Bowes S; Josiah S; Lee WC; Singh J; Ling LE; Varga J J Invest Dermatol; 2006 Aug; 126(8):1733-44. PubMed ID: 16741519 [TBL] [Abstract][Full Text] [Related]
9. Silibinin inhibits myofibroblast transdifferentiation in human tenon fibroblasts and reduces fibrosis in a rabbit trabeculectomy model. Chen YH; Liang CM; Chen CL; Chen JT; Chang YH; Lu DW; Chien KH; Tai MC Acta Ophthalmol; 2013 Nov; 91(7):e506-15. PubMed ID: 23764119 [TBL] [Abstract][Full Text] [Related]
11. Vitamin D receptor regulates TGF-β signalling in systemic sclerosis. Zerr P; Vollath S; Palumbo-Zerr K; Tomcik M; Huang J; Distler A; Beyer C; Dees C; Gela K; Distler O; Schett G; Distler JH Ann Rheum Dis; 2015 Mar; 74(3):e20. PubMed ID: 24448349 [TBL] [Abstract][Full Text] [Related]
12. Metabolic reprogramming of glycolysis and glutamine metabolism are key events in myofibroblast transition in systemic sclerosis pathogenesis. Henderson J; Duffy L; Stratton R; Ford D; O'Reilly S J Cell Mol Med; 2020 Dec; 24(23):14026-14038. PubMed ID: 33140521 [TBL] [Abstract][Full Text] [Related]
13. 5-HT Chaturvedi S; Misra DP; Prasad N; Rastogi K; Singh H; Rai MK; Agarwal V Int J Rheum Dis; 2018 Dec; 21(12):2128-2138. PubMed ID: 30207074 [TBL] [Abstract][Full Text] [Related]
14. Constitutive ALK5-independent c-Jun N-terminal kinase activation contributes to endothelin-1 overexpression in pulmonary fibrosis: evidence of an autocrine endothelin loop operating through the endothelin A and B receptors. Shi-Wen X; Rodríguez-Pascual F; Lamas S; Holmes A; Howat S; Pearson JD; Dashwood MR; du Bois RM; Denton CP; Black CM; Abraham DJ; Leask A Mol Cell Biol; 2006 Jul; 26(14):5518-27. PubMed ID: 16809784 [TBL] [Abstract][Full Text] [Related]
17. [Transdifferentiation of fibroblasts into myofibroblasts in the skin lesion of systemic sclerosis: role of transforming growth factor β1 and its signal transduction]. Liu T; Hu XD Nan Fang Yi Ke Da Xue Xue Bao; 2011 Nov; 31(11):1840-5. PubMed ID: 22126761 [TBL] [Abstract][Full Text] [Related]
18. Knockout of endothelin type B receptor signaling attenuates bleomycin-induced skin sclerosis in mice. Akashi K; Saegusa J; Sendo S; Nishimura K; Okano T; Yagi K; Yanagisawa M; Emoto N; Morinobu A Arthritis Res Ther; 2016 May; 18(1):113. PubMed ID: 27209208 [TBL] [Abstract][Full Text] [Related]
19. RNA interference against platelet-derived growth factor receptor α mRNA inhibits fibroblast transdifferentiation in skin lesions of patients with systemic sclerosis. Liu T; Zhang J; Zhang J; Mu X; Su H; Hu X; Liu W; Zhao E; Li W PLoS One; 2013; 8(4):e60414. PubMed ID: 23577108 [TBL] [Abstract][Full Text] [Related]
20. Macitentan slows down the dermal fibrotic process in systemic sclerosis: in vitro findings. Corallo C; Pecetti G; Iglarz M; Volpi N; Franci D; Montella A; D' Onofrio F; Nuti R; Giordano N J Biol Regul Homeost Agents; 2013; 27(2):455-62. PubMed ID: 23830395 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]